10-Q: PepGen Inc. Reports Second Quarter 2024 Financial Results and Provides Clinical Program Update

PepGen Inc. reports a net loss of $46.4 million for the first six months of 2024, while highlighting progress in clinical trials for its lead product candidates.

Summary

• PepGen Inc., a clinical-stage biotechnology company, reported a net loss of $46.4 million for the six months ended June 30, 2024, compared to a net loss of $35.8 million for the same period in 2023.
• The company's research and development expenses increased to $39.8 million for the first six months of 2024, up from $31.3 million in the same period of 2023, driven by the advancement of clinical trials for PGN-EDO51 and PGN-EDODM1.
• General and administrative expenses also rose to $10.4 million for the first six months of 2024, compared to $7.9 million in the same period of 2023, primarily due to increased personnel costs.
• As of June 30, 2024, PepGen had cash, cash equivalents, and marketable securities totaling $161.3 million.
• The company believes its current cash position will be sufficient to fund operations into 2026.
• PepGen completed a follow-on offering in February 2024, resulting in net proceeds of $76.4 million.
• The company also sold shares under its at-the-market offering program, resulting in net proceeds of $9.9 million.
• Initial data from the CONNECT1 study of PGN-EDO51 showed a mean exon skipping of 2.15% in biceps tissue at week 13, with a mean muscle-adjusted dystrophin level of 1.49% of normal.
• The 5 mg/kg dose of PGN-EDO51 was well tolerated in the CONNECT1 study, with no discontinuations, dose interruptions, or dose reductions.
• The company expects to report initial results from the 10 mg/kg cohort of the CONNECT1 study in early 2025.
• PepGen plans to initiate patient dosing in the FREEDOM2 Phase 2 study of PGN-EDODM1 in the second half of 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company shows progress in clinical trials and has a strong cash position, the increasing losses and reliance on future funding are concerning. The initial clinical data is promising, but the overall financial picture is not yet positive.

Positives

• The company has a strong cash position of $161.3 million, which is expected to fund operations into 2026.
• Initial data from the CONNECT1 study of PGN-EDO51 showed promising results in terms of exon skipping and dystrophin production.
• PGN-EDO51 was well tolerated in the CONNECT1 study at the 5 mg/kg dose.
• The company has received regulatory clearance to initiate the CONNECT2 study in the U.K. and the FREEDOM2 study in Canada and the U.K.
• The company has made progress in advancing its clinical programs for both DMD and DM1.

Negatives

• The company reported a net loss of $46.4 million for the first six months of 2024, an increase from $35.8 million in the same period of 2023.
• Research and development expenses have increased significantly, driven by the advancement of clinical trials.
• The company has not generated any revenue from product sales and is dependent on additional financing.
• The company is still in the early stages of development and faces significant risks and uncertainties.

Risks

• The company has incurred significant losses since its inception and expects to incur losses for the foreseeable future.
• The company will need to raise substantial additional funding, and if unable to do so, may be forced to delay or discontinue product development programs.
• The company is early in its development efforts, and it will be years before it commercializes a product candidate, if ever.
• Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome.
• The company relies on third parties for manufacturing, research, and testing, and these third parties may not perform satisfactorily.
• The company faces significant competition, and competitors may develop more effective or safer products.
• The company may not be able to obtain and maintain patent protection for its technologies.
• The price of the company's common stock is volatile and fluctuates substantially.

Future Outlook

The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2026. The company expects to increase research and development expenses as it continues clinical trials and advances preclinical programs. The company also expects to continue to incur additional costs associated with operating as a public company.

Management Comments

• Based on our currently planned operations, we believe that our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations into 2026.
• We expect our expenses and operating losses will continue as we conduct our ongoing preclinical studies and current and planned clinical trials, continue our research and development activities, utilize third parties to manufacture our product candidates and related raw materials, hire additional personnel, protect our intellectual property and incur additional costs associated with being a public company.

Industry Context

The announcement reflects the ongoing challenges and high costs associated with drug development in the biotechnology sector, particularly for companies focused on rare diseases. The company is competing with other companies developing similar therapies, including gene therapies and other oligonucleotide-based approaches.

Comparison to Industry Standards

• The reported net loss and increased R&D expenses are typical for a clinical-stage biotechnology company advancing multiple programs.
• The cash runway into 2026 is relatively strong compared to many other companies in the sector, providing financial stability for ongoing clinical trials.
• The initial clinical data from the CONNECT1 study, while early, is promising and compares favorably to other exon-skipping approaches in development.
• The company's approach of using peptide-conjugated oligonucleotides is a novel approach, and the results will be closely watched by the industry.
• The company's ability to secure regulatory clearances for its clinical trials in multiple countries is a positive sign of its regulatory strategy.

Corporate Governance

Legal Proceedings

• As of June 30, 2024, the company was not a party to any material legal proceedings.

Related Party Transactions

• The company has a Technology License Agreement with Oxford University Innovation Limited, or OUI, and the Medical Research Council of United Kingdom Research and Innovation, or MRC.
• One member of the company's board of directors, Dr. Christopher Ashton, is also employed by Oxford Science Enterprises, or OSE, which is an affiliate of OUI.
• Entities affiliated with RA Capital Management, L.P., or RA Capital, purchased common stock in the company's IPO and Follow-on Offering.
• Two members of the company's board of directors, Dr. Joshua Resnick and Habib Dable, are affiliated with RA Capital.

Stakeholder Impact

• Shareholders may be concerned about the increasing losses and the need for additional funding.
• Employees may be affected by the company's growth and expansion plans.
• Patients may benefit from the company's progress in developing new therapies for DMD and DM1.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company expects to report initial results from the 10 mg/kg cohort of the CONNECT1 study in early 2025.
• PepGen plans to initiate patient dosing in the FREEDOM2 Phase 2 study of PGN-EDODM1 in the second half of 2024.
• The company will continue to engage with regulators in the European Union regarding the CONNECT2 study and expects to file an investigational new drug application and open the clinical trial in the United States by year-end.

Key Dates

Keywords

PepGen, Oligonucleotide Therapeutics, Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1, PGN-EDO51, PGN-EDODM1, Clinical Trials, Exon Skipping, Dystrophin, Biotechnology